Derangement of immune responses by myeloid suppressor cells.
In tumor-bearing mice and cancer patients, tumor progression is often associated with altered hematopoiesis leading to the accumulation of myeloid cells. Extensive studies in preclinical models indicate that these cells share the CD11b and the Gr-1 markers, possess a mixed mature-immature myeloid phenotype, and are responsible for the induction of T-cell dysfunctions, both tumor-specific and nonspecific. Moreover, CD11b(+)Gr-1(+) myeloid cells are described under different unrelated situations associated with temporary impairment of the T-lymphocyte reactivity. This review examines recent findings on the nature, properties, and mechanisms of action of these myeloid suppressor cells (MSCs).
Department of Oncology and Surgical Sciences, Oncology Section, Azienda Ospedaliera, Via Gattamelata 64, 35128, Padova, Italy.
Paolo
P
Serafini
Carmela
C
De Santo
Ilaria
I
Marigo
Sara
S
Cingarlini
Luigi
L
Dolcetti
Giovanna
G
Gallina
Paola
P
Zanovello
Vincenzo
V
Bronte
D000818:Animals; D006410:Hematopoiesis; D006801:Humans; D007108:Immune Tolerance / Q000276:immunology*; D007153:Immunologic Deficiency Syndromes / Q000209:etiology*; D022423:Myeloid Cells / Q000276:immunology*; D009369:Neoplasms / Q000150:complications / Q000276:immunology*; D015375:Receptors, Interleukin-2 / Q000276:immunology; D015398:Signal Transduction / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology
D015375:Receptors, Interleukin-2